TY - JOUR
T1 - Oral lipoic acid as a treatment for acute optic neuritis
T2 - a blinded, placebo controlled randomized trial
AU - Falardeau, Julie
AU - Fryman, Allison
AU - Wanchu, Rohan
AU - Marracci, Gail H.
AU - Mass, Michele
AU - Wooliscroft, Lindsey
AU - Bourdette, Dennis N.
AU - Murchison, Charles F.
AU - Hills, William L.
AU - Yadav, Vijayshree
N1 - Publisher Copyright:
© 2019, SAGE Publications Inc. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Background: Lipoic acid, an antioxidant, has beneficial effects in experimental acute optic neuritis and autoimmune encephalomyelitis. Optical coherence tomography can detect retinal nerve fiber layer thinning, representing axonal degeneration, approximately 3–6 months after acute optic neuritis. Objective: To determine whether lipoic acid is neuroprotective in acute optic neuritis. Methods: A single-center, double-blind, randomized, placebo controlled, 24-week trial. Intervention included 6 weeks of once daily lipoic acid (1200 mg) or placebo within 14 days of acute optic neuritis diagnosis. The primary outcome was the mean difference in affected eye retinal nerve fiber layer (RNFL) thickness from baseline to 24 weeks. Results: We enrolled 31 subjects (placebo n¼16; lipoic acid n¼15; average age 38.6 years (standard deviation (SD) 10.3)). Affected eye mean global RNFL thickness (mm) in the lipoic acid group decreased from 108.47 (SD 26.11) at baseline to 79.31 (SD 19.26) at 24 weeks. The affected eye RNFL in the placebo group decreased from 103.67 (SD 18.04) at baseline to 84.43 (SD 20.94) at 24 weeks. Unaffected eye RNFL thickness did not significantly change in either group over 24 weeks. Conclusion: Six weeks of oral lipoic acid supplementation after acute optic neuritis is safe and well tolerated; however, because of insufficient recruitment, we could not conclude that lipoic acid treatment was neuroprotective in acute optic neuritis.
AB - Background: Lipoic acid, an antioxidant, has beneficial effects in experimental acute optic neuritis and autoimmune encephalomyelitis. Optical coherence tomography can detect retinal nerve fiber layer thinning, representing axonal degeneration, approximately 3–6 months after acute optic neuritis. Objective: To determine whether lipoic acid is neuroprotective in acute optic neuritis. Methods: A single-center, double-blind, randomized, placebo controlled, 24-week trial. Intervention included 6 weeks of once daily lipoic acid (1200 mg) or placebo within 14 days of acute optic neuritis diagnosis. The primary outcome was the mean difference in affected eye retinal nerve fiber layer (RNFL) thickness from baseline to 24 weeks. Results: We enrolled 31 subjects (placebo n¼16; lipoic acid n¼15; average age 38.6 years (standard deviation (SD) 10.3)). Affected eye mean global RNFL thickness (mm) in the lipoic acid group decreased from 108.47 (SD 26.11) at baseline to 79.31 (SD 19.26) at 24 weeks. The affected eye RNFL in the placebo group decreased from 103.67 (SD 18.04) at baseline to 84.43 (SD 20.94) at 24 weeks. Unaffected eye RNFL thickness did not significantly change in either group over 24 weeks. Conclusion: Six weeks of oral lipoic acid supplementation after acute optic neuritis is safe and well tolerated; however, because of insufficient recruitment, we could not conclude that lipoic acid treatment was neuroprotective in acute optic neuritis.
KW - Multiple sclerosis
KW - intervention
KW - lipoic acid
KW - optic neuritis
UR - http://www.scopus.com/inward/record.url?scp=85093099012&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85093099012&partnerID=8YFLogxK
U2 - 10.1177/2055217319850193
DO - 10.1177/2055217319850193
M3 - Article
AN - SCOPUS:85093099012
SN - 2055-2173
VL - 5
JO - Multiple Sclerosis Journal - Experimental, Translational and Clinical
JF - Multiple Sclerosis Journal - Experimental, Translational and Clinical
IS - 2
ER -